Prevail Therapeutics Announces Executive Team Promotion and Appointments to Board of Directors
Yong Dai, Ph.D., Promoted to Chief Technology Officer Tim Adams Joins Board of Directors; Francois Nader, M.D., Role Expanded to…
Pharmaceuticals, Biotechnology and Life Sciences
Yong Dai, Ph.D., Promoted to Chief Technology Officer Tim Adams Joins Board of Directors; Francois Nader, M.D., Role Expanded to…
Accepted abstracts highlight additional data from phase 3 ARIEL3 clinical trial, genomic data from phase 2 TRITON2 clinical trial, and…
Access to Resero’s TurboToxicology™ will provide faster delivery of high-quality toxicology reports WILMINGTON, Mass.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24CRL&src=ctag" target="_blank"gt;$CRLlt;/agt; lt;a href="https://twitter.com/hashtag/LIFEatCRL?src=hash" target="_blank"gt;#LIFEatCRLlt;/agt;–Charles…
Boehringer Ingelheim’s the trial did not meet its primary endpoint, which was to show aclinically significant difference between dabigatran etexilate and ASAon reducing the risk of a recurrent stroke among post-stroke patientswith ESUS.
Biomarker research to provide deeper understanding of mechanism of action, relationship between efficacy and adverse events OXFORDSHIRE, England & CONSHOHOCKEN,…
The “Takeda Chair in Global Child Health” is the first Chair at the London School of Hygiene & Tropical Medicine…
WESTPORT, Conn.–(BUSINESS WIRE)–Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based approach to treat solid tumor cancers through…
— Clinical Proof-of-Concept Data Expected in Fourth Quarter of 2019 — CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company”…
MILPITAS, Calif.–(BUSINESS WIRE)–ASC Therapeutics, A Division of Applied StemCell, Inc. (ASC), announced today that it has obtained an exclusive therapeutics…
Company to host conference call following ASCO presentation on June 2 to discuss updated clinical data DARTMOUTH, Nova Scotia–(BUSINESS WIRE)–IMV…